- Home
- SRRK
as 10-24-2025 3:52pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 3.0B | IPO Year: | 2018 |
| Target Price: | $47.88 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.71 - $46.98 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1911.27% |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | SRRK | Director | Oct 6 '25 | Buy | $38.70 | 113,025 | $4,368,808.26 | 405,828 | |
| AKKARAJU SRINIVAS | SRRK | Director | Oct 3 '25 | Buy | $36.59 | 387,414 | $14,438,543.93 | 405,828 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Sep 22 '25 | Sell | $30.67 | 3,353 | $102,846.23 | 108,964 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Sep 16 '25 | Sell | $33.52 | 3,178 | $106,526.56 | 108,964 | |
| Peng Katie | SRRK | Director | Sep 16 '25 | Sell | $32.84 | 1,006 | $32,725.69 | 33,914 | |
| Parlavecchio Caryn | SRRK | CHRO | Aug 18 '25 | Sell | $31.17 | 2,178 | $67,880.20 | 155,464 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Scholar Rock (SRRK): Is the Current Valuation Justified After Recent Share Price Drop?
Barrons.com
7 days ago
Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors
Business Wire
7 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/7 Wall St.
7 days ago
Insiders Bet Big on These 3 Fintech and Biotech Stocks
Simply Wall St.
18 days ago
Scholar Rock (SRRK): Assessing Valuation Following FDA Setback for Apitegromab Approval
Investor's Business Daily
a month ago
Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback
MT Newswires
a month ago
HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating
MT Newswires
a month ago
Sector Update: Health Care Stocks Advance Premarket Tuesday
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.